OLUX E
Clinical safety rating: caution
Comprehensive clinical and safety monograph for OLUX E (OLUX E).
Clobetasol propionate is a high-potency corticosteroid that induces phospholipase A2 inhibitory proteins (lipocortins), inhibiting arachidonic acid release, thereby reducing prostaglandin and leukotriene synthesis, producing anti-inflammatory, antipruritic, and vasoconstrictive effects.
| Metabolism | Primarily metabolized in the liver via CYP3A4, though topical application yields minimal systemic absorption. Metabolism involves reduction and conjugation. |
| Excretion | Primarily hepatic metabolism and renal excretion of metabolites; <5% unchanged in urine. |
| Half-life | Terminal half-life approximately 5-6 hours; clinical context: supports twice-daily dosing. |
| Protein binding | Approximately 90% bound to albumin and corticosteroid-binding globulin. |
| Volume of Distribution | Vd ~1.4 L/kg; indicates distribution into total body water with some tissue binding. |
| Bioavailability | Percutaneous absorption ~1-3% via intact skin; higher if occluded or skin compromised. |
| Onset of Action | Topical: clinical improvement noted within 2-3 weeks of regular use. |
| Duration of Action | After discontinuation, effects may persist for 1-2 weeks; relapse occurs if underlying condition remains. |
Topical application of a thin layer to affected areas once or twice daily, not exceeding 50 g per week.
| Dosage form | AEROSOL, FOAM |
| Renal impairment | No dosage adjustment required for renal impairment. |
| Liver impairment | No dosage adjustment required for hepatic impairment. |
| Pediatric use | Not recommended for use in children under 12 years of age due to increased risk of systemic corticosteroid effects. |
| Geriatric use | Use with caution in elderly patients due to increased susceptibility to skin atrophy and systemic effects; limit use to smallest area and shortest duration. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for OLUX E (OLUX E).
| Breastfeeding | It is not known whether topical clobetasol propionate is excreted in human milk. Systemic absorption is minimal after topical application; however, significant absorption could occur with prolonged or extensive use. Use with caution, and avoid application to the breast area. No M/P ratio available. |
| Teratogenic Risk | Olux-E (clobetasol propionate) is a high-potency topical corticosteroid. Systemic absorption is minimal with topical use, but prolonged or extensive use may increase risk. In animal studies, corticosteroids have been shown to be teratogenic (cleft palate, skeletal abnormalities) at relatively low systemic doses. Human data are limited; however, the potential for fetal harm cannot be ruled out. Use during pregnancy only if the potential benefit justifies the risk to the fetus. First trimester: Avoid use unless essential. Second/third trimester: Limited data; avoid large areas, prolonged use, or occlusive dressings. |
■ FDA Black Box Warning
No FDA boxed warning exists for this topical product.
| Serious Effects |
["Hypersensitivity to clobetasol propionate or any excipient","Uninfected skin lesions (viral, bacterial, fungal)","Rosacea, perioral dermatitis, skin atrophy"]
| Precautions | ["Systemic absorption may produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, hyperglycemia, and glucosuria.","Use should be limited to 2 consecutive weeks and not exceed 50 g/week.","Avoid use in patients with skin atrophy, rosacea, perioral dermatitis, or bacterial/fungal infections.","Apply only to affected areas; avoid occlusive dressings unless directed.","Pediatric patients may be more susceptible to systemic toxicity."] |
Loading safety data…
| Fetal Monitoring | Monitor maternal adrenal function (e.g., ACTH stimulation test) if prolonged or extensive use occurs. Monitor fetal growth with ultrasound if high-dose or prolonged use during pregnancy. Assess for signs of HPA axis suppression in the neonate if maternal use was high-dose or prolonged. |
| Fertility Effects | No specific data on fertility effects in humans. Animal studies with corticosteroids have shown reduced fertility. Topical clobetasol propionate is unlikely to significantly impact fertility due to minimal systemic absorption. |